SELLAS Life Sciences Group, Inc.

1.06 USD
-0.01 (-1.40%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

SELLAS Life Sciences Group, Inc. stock is up 8.76% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 15.38% of the previous 12 December’s closed higher than November. 100% of analysts rate it a buy.

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapy that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials. The company was founded in 2012 and is headquartered in New York, New York.